Please login to the form below

Not currently logged in

Nycomed wins EC approval for Instanyl

The EC has granted Nycomed marketing authorisation for its Instanyl single-dose nasal spray

The European Commission (EC) has granted Nycomed marketing authorisation for its Instanyl single-dose nasal spray.

The spray is approved for the management of breakthrough pain in cancer patients, and was first approved in Europe as a multi-dose nasal spray in 2009.

The launch of the single-dose spray will provide greater flexibility to the patient and help to manage dose titration and dose modification, as well as enabling easier tracking of patient's use of rescue medication, according to Nycomed.

Guido Oelkers, executive vice president at the company, said: "Development of the Instanyl single-dose nasal spray further demonstrates Nycomed's commitment to innovation in areas of clear medical need. Over half a million cancer patients are suffering from breakthrough pain in Europe. The Instanyl single-dose nasal spray will add flexibility to the managing of their pain."

The single-dose nasal spray will be available in 50 µg, 100 µg, and 200 µg doses.

4th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
How Helpful are Simple Health Messages?